Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2026)

Caris Life Sciences' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 1129.93% YoY), while the FY2025 annual figure was $1.1 billion, up 227.48% from the prior year.
• Liabilities and Shareholders Equity was $1.2 billion for Q1 2026 at Caris Life Sciences, up from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2026 to a low of $343.7 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $914.3 million across 3 years, with a median of $984.6 million in 2025.
• Biggest YoY gain for Liabilities and Shareholders Equity was 227.48% in 2025; the steepest drop was 227.48% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $343.7 million in 2024, then soared by 227.48% to $1.1 billion in 2025, then increased by 3.26% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $984.6 million (Q3 2025), per Business Quant data.